Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Chow

Showing results (411-420 of 412) with videos related to

Pageof 42
Sort By:
You have reached the last page of results.This site can display upto 412 results.
Journal of Medicinal Chemistry|March 4, 2008
Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degenerationMoorthy S S Palanki, Hideo Akiyama, Peter Campochiaro, et al.
Bioorganic & Medicinal Chemistry Letters|November 23, 2006
Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assaysGlenn Noronha, Kathy Barrett, Antonio Boccia, et al.
Pageof 42

Showing results (411-420 of 412) with videos related to

Sort By:
Pageof 42
You have reached the last page of results.This site can display upto 412 results.
Journal of Medicinal Chemistry|March 4, 2008
Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degenerationMoorthy S S Palanki, Hideo Akiyama, Peter Campochiaro, et al.
Bioorganic & Medicinal Chemistry Letters|November 23, 2006
Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assaysGlenn Noronha, Kathy Barrett, Antonio Boccia, et al.
Pageof 42